Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intracellular redox client proteins in cone photoreceptors are a group of proteins whose functional state is maintained through thiol-disulfide exchange, primarily regulated by the thioredoxin-like enzyme Rod-derived Cone Viability Factor-Long (RdCVF-L), encoded by the NXNL1 gene (Fridlich et al., 2009, PubMed: 19228697). These proteins are essential for the structural integrity and metabolic health of cone cells, which are responsible for high-acuity and color vision. In degenerative retinal diseases such as Retinitis Pigmentosa, the progressive loss of rod cells leads to a deficiency in RdCVF-L, causing these client proteins to remain in an oxidized, often dysfunctional or aggregated state (Leveillard & Sahel, 2010, PubMed: 20603591). One well-characterized client is the microtubule-associated protein tau (MAPT), which requires reduction by RdCVF-L to maintain cytoskeletal stability and prevent hyperphosphorylation (SparingVision, 2023). Therapeutic interventions like the gene therapy SPVN06 aim to deliver RdCVF-L to the retina to restore the redox homeostasis of these client proteins, thereby preventing cone death regardless of the underlying genetic mutation (Byrne et al., 2015, PubMed: 25915124). This mutation-agnostic approach addresses the secondary oxidative stress that typically leads to total blindness in patients with inherited retinal degenerations.
Restoration of the reduced state of intracellular proteins via the thioredoxin-like activity of RdCVF-L, preventing oxidative damage and metabolic failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intracellular redox client proteins in cone photoreceptors.